Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 78-79
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic
Ali A. Rabaan, Shamsah H. Al-Ahmed, Ranjit Sah, et al.
Annals of Clinical Microbiology and Antimicrobials (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 134
COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
Ramandeep Singh, Alisha Kang, Xiang‐Qian Luo, et al.
The FASEB Journal (2021) Vol. 35, Iss. 3
Open Access | Times Cited: 95
Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story
Amin Gasmi, Massimiliano Peana, Sàdaf Noor, et al.
Applied Microbiology and Biotechnology (2021) Vol. 105, Iss. 4, pp. 1333-1343
Open Access | Times Cited: 84
The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic
Allan Tran, Theodore J. Witek
Pharmaceutical Medicine (2021) Vol. 35, Iss. 4, pp. 203-213
Open Access | Times Cited: 52
Characteristics, quality and volume of the first 5 months of the COVID-19 evidence synthesis infodemic: a meta-research study
Rebecca Abbott, Alison Bethel, Morwenna Rogers, et al.
BMJ evidence-based medicine (2021) Vol. 27, Iss. 3, pp. 169-177
Open Access | Times Cited: 45
The role of antirheumatics in patients with COVID-19
Christoffer B Nissen, Savino Sciascia, Danieli Andrade, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 6, pp. e447-e459
Open Access | Times Cited: 41
Continuous tracking of COVID-19 patients' immune status
Jingjing Guan, Xin Wei, Shuang Qin, et al.
International Immunopharmacology (2020) Vol. 89, pp. 107034-107034
Open Access | Times Cited: 43
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider
Alessia Alunno, Aurélie Najm, Xavier Mariette, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 6, pp. 803-815
Open Access | Times Cited: 38
Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Alina Dima, Ciprian Jurcuț, Laurent Arnaud
Joint Bone Spine (2021) Vol. 88, Iss. 3, pp. 105143-105143
Closed Access | Times Cited: 37
QTc prolongation in COVID‐19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta‐analysis
Carlos Díaz-Arocutipa, Ana Brañez‐Condorena, Adrían V. Hernández
Pharmacoepidemiology and Drug Safety (2021) Vol. 30, Iss. 6, pp. 694-706
Open Access | Times Cited: 36
Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda
Jonathan Kitonsa, Onesmus Kamacooko, Ubaldo Bahemuka, et al.
PLoS ONE (2021) Vol. 16, Iss. 5, pp. e0251992-e0251992
Open Access | Times Cited: 25
Emerging Therapeutic Modalities against COVID-19
Shipra Malik, Anisha Gupta, Xiao‐bo Zhong, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 8, pp. 188-188
Open Access | Times Cited: 26
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 11, pp. W156-W157
Open Access | Times Cited: 26
Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation
Elie A. Akl, Joanne Khabsa, Claire Iannizzi, et al.
BMJ (2024), pp. e079183-e079183
Open Access | Times Cited: 2
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 7, pp. W128-W129
Open Access | Times Cited: 23
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
Urs Thomet, Bogdan Amuzescu, Thomas Knott, et al.
European Journal of Pharmacology (2021) Vol. 913, pp. 174632-174632
Open Access | Times Cited: 19
Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement
Farrah Madanay, Ryan C. McDevitt, Peter A. Ubel
Journal of Health Politics Policy and Law (2022) Vol. 47, Iss. 4, pp. 429-451
Closed Access | Times Cited: 12
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians
Amir Qaseem, Jennifer Yost, Itziar Etxeandia‐Ikobaltzeta, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 2, pp. W48-W51
Open Access | Times Cited: 20
Evidence in decision-making in the context of COVID-19 in Latin America
Victoria Stanford, Lionel Gresh, João Toledo, et al.
The Lancet Regional Health - Americas (2022) Vol. 14, pp. 100322-100322
Open Access | Times Cited: 11
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians
Amir Qaseem, Jennifer Yost, Itziar Etxeandia‐Ikobaltzeta, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 5, pp. W88-W89
Open Access | Times Cited: 17
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
Elisa Baranski Lamback, Mônica Amorim de Oliveira, Andréa Ferreira Haddad, et al.
The Brazilian Journal of Infectious Diseases (2021) Vol. 25, Iss. 2, pp. 101549-101549
Open Access | Times Cited: 15
Pharmacological management of COVID-19 in type 2 diabetes
Antonio Ceriello, Francesco Prattichizzo
Journal of Diabetes and its Complications (2021) Vol. 35, Iss. 7, pp. 107927-107927
Open Access | Times Cited: 15
Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis
Suzana Érico Tanni, Hélio Arthur Bacha, Alexandre Naime Barbosa, et al.
Jornal Brasileiro de Pneumologia (2021), pp. e20210236-e20210236
Open Access | Times Cited: 15
Rise and Fall: Hydroxychloroquine and COVID‐19 Global Trends: Interest, Political Influence, and Potential Implications
Tessa R. Englund, Alan C. Kinlaw, Saira Z. Sheikh
ACR Open Rheumatology (2020) Vol. 2, Iss. 12, pp. 760-766
Open Access | Times Cited: 15
Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis
Adrían V. Hernández, Mi T. Phan, Jonathon Rocco, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2503-2503
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top